Expression of Alternatively Spliced Human Tissue Factor

选择性剪接的人组织因子的表达

• 批准号: 7015080
• 负责人: VLADIMIR BOGDANOV
• 金额: $ 11.35万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-07 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7015080
• 关键词: RNA interference; RNA splicing; cell line; gene induction /repression; genetic regulatory element; human genetic material tag; lipopolysaccharides; nucleic acid structure; thromboplastin

DESCRIPTION (provided by applicant): I, Vladimir Bogdanov, am applying for this research development award in order to finalize my transition into an independent research scientist. The immediate goals are: 1) to acquire new laboratory skills and generate novel research data that would enable me to compete for regular research project grant support (RO1), 2) to acquire first-hand experience in being a principal investigator, and 3) to make substantial progress in elucidating the mechanisms involved in regulation of human tissue factor (TF) pre-mRNA processing in monocytic cells. Specifically, I propose to study regulatory mechanisms responsible for generation of alternatively spliced human tissue factor (asHTF) in monocytes. asHTF, a recently identified molecule, is a soluble, biologically active form of human tissue factor generated by alternative splicing. It is present in circulating blood and thrombi and interacts with platelets under shear conditions. Full-length membrane-bound TF and asHTF are both present in arterial and ex-vivo thrombi. Initial results show that circulating monocytes serve as one of the major sources of asHTF protein in human plasma. Thus, mechanics of tissue factor pre-mRNA splicing in monocytic cells is the primary research objective of the proposed study. In addition, I propose to achieve selective down-regulation of full-length membrane bound TF and asHTF mRNA in monocytic cells by a novel technique of RNA interference and assess the impact of this down-regulation on the total coagulant potential of monocytic cells.

描述（由申请人提供）： 我，弗拉基米尔·波格丹诺夫，申请这个研究发展奖是为了完成我向独立研究科学家的转变。近期目标是：1）获得新的实验室技能，并产生新的研究数据，使我能够竞争定期研究项目资助支持（RO1），2）获得作为主要研究者的第一手经验，3）在阐明单核细胞中人类组织因子（TF）前mRNA加工调节机制方面取得实质性进展。具体来说，我建议研究的监管机制，负责产生的选择性剪接的人组织因子（asHTF）在单核细胞。asHTF是最近鉴定的分子，是由可变剪接产生的可溶性生物活性形式的人组织因子。它存在于循环血液和血栓中，并在剪切条件下与血小板相互作用。全长膜结合TF和asHTF都存在于动脉和离体血栓中。初步结果表明，循环单核细胞作为人血浆中asHTF蛋白的主要来源之一。因此，单核细胞中组织因子前体mRNA剪接的机制是拟议研究的主要研究目标。此外，我建议实现选择性下调全长膜结合TF和asHTF mRNA在单核细胞中的一种新的RNA干扰技术，并评估这种下调对单核细胞的总凝血潜力的影响。